RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Deciphera Pharmaceuticals Stock

Deciphera Pharmaceuticals P/S 2024

Deciphera Pharmaceuticals P/S

10.57

Ticker

DCPH

ISIN

US24344T1016

WKN

A2H48H

As of Oct 1, 2024, Deciphera Pharmaceuticals's P/S ratio stood at 10.57, a 47.63% change from the 7.16 P/S ratio recorded in the previous year.

The Deciphera Pharmaceuticals P/S history

Deciphera Pharmaceuticals Aktienanalyse

What does Deciphera Pharmaceuticals do?

Deciphera Pharmaceuticals Inc is a US biopharmaceutical company specializing in the research, development, and marketing of innovative therapeutic solutions for cancer patients. The company was founded in 2003 and is headquartered in Waltham, Massachusetts. Deciphera follows a diversified business model based on multiple pillars. On one hand, the company conducts its own research and development activities to develop new therapy approaches for cancer patients. Deciphera focuses on the research of kinase inhibitors, which offer promising approaches in cancer therapy. On the other hand, the company pursues a licensing strategy by acquiring and further developing already developed active ingredients for cancer therapies in order to make them available to patients. For this purpose, the company collaborates with various partner companies and leading academics and experts in the field of cancer therapy. Deciphera is also engaged in international collaboration through partnerships with local partners in Asia for the research of new cancer therapy approaches. The company invests significant efforts in research and development to constantly adapt its products to the latest scientific advances. Deciphera aims to develop effective and safe therapies for cancer patients that improve their quality of life and increase their chances of survival. The company relies on the research of kinase inhibitors that specifically target certain signaling pathways in cancer cells and thereby inhibit the growth of tumor cells. The company already has a number of products in clinical trials and approval processes that show promising results and are expected to be on the market soon. One promising drug is Ripretinib, dedicated to the cancer type GIST. The goal is to offer a range of cancer medications that have significant treatment success and offer customers high chances of success. Overall, Deciphera Pharmaceuticals is a dynamic and research-oriented company that utilizes the most innovative technologies to give hope to cancer patients and improve the treatment of cancer diseases. With its broad portfolio of active ingredients and therapy approaches, its international presence, and its dedicated research and development, Deciphera Pharmaceuticals Inc. is at the forefront when it comes to innovative cancer treatment therapies. Deciphera Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/S Details

Decoding Deciphera Pharmaceuticals's P/S Ratio

Deciphera Pharmaceuticals's Price to Sales (P/S) Ratio is a crucial financial metric that measures the company's market valuation relative to its total sales revenue. It's calculated by dividing the company's market capitalization by its total sales over a specific period. A lower P/S ratio can indicate that the company is undervalued, while a higher ratio may suggest overvaluation.

Year-to-Year Comparison

Comparing Deciphera Pharmaceuticals's P/S ratio yearly provides insights into how the market perceives the company’s value relative to its sales. An increasing ratio over time can indicate growing investor confidence, while a decreasing trend might reflect concerns about the company’s revenue generation capabilities or market conditions.

Impact on Investments

The P/S ratio is instrumental for investors evaluating Deciphera Pharmaceuticals's stock. It offers insights into the company’s efficiency in generating sales and its market valuation. Investors use this ratio to compare similar companies within the same industry, aiding in selecting stocks that offer the best value for investment.

Interpreting P/S Ratio Fluctuations

Variations in Deciphera Pharmaceuticals’s P/S ratio can result from changes in the stock price, sales revenue, or both. Understanding these fluctuations is crucial for investors to evaluate the company’s current valuation and future growth potential, aligning their investment strategies accordingly.

Frequently Asked Questions about Deciphera Pharmaceuticals stock

What is the price-to-earnings ratio of Deciphera Pharmaceuticals?

The price-earnings ratio of Deciphera Pharmaceuticals is currently 10.57.

How has the price-earnings ratio of Deciphera Pharmaceuticals changed compared to last year?

The price-to-earnings ratio of Deciphera Pharmaceuticals has increased by 47.63% increased compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of Deciphera Pharmaceuticals high compared to other companies?

Yes, the price-to-earnings ratio of Deciphera Pharmaceuticals is high compared to other companies.

How does an increase in the price-earnings ratio of Deciphera Pharmaceuticals affect the company?

An increase in the price-earnings ratio of Deciphera Pharmaceuticals would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of Deciphera Pharmaceuticals affect the company?

A decrease in the price-earnings ratio of Deciphera Pharmaceuticals would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of Deciphera Pharmaceuticals?

Some factors that influence the price-earnings ratio of Deciphera Pharmaceuticals are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does Deciphera Pharmaceuticals pay?

Over the past 12 months, Deciphera Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Deciphera Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Deciphera Pharmaceuticals?

The current dividend yield of Deciphera Pharmaceuticals is .

When does Deciphera Pharmaceuticals pay dividends?

Deciphera Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Deciphera Pharmaceuticals?

Deciphera Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Deciphera Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Deciphera Pharmaceuticals located?

Deciphera Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Deciphera Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Deciphera Pharmaceuticals from 10/1/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/1/2024.

When did Deciphera Pharmaceuticals pay the last dividend?

The last dividend was paid out on 10/1/2024.

What was the dividend of Deciphera Pharmaceuticals in the year 2023?

In the year 2023, Deciphera Pharmaceuticals distributed 0 USD as dividends.

In which currency does Deciphera Pharmaceuticals pay out the dividend?

The dividends of Deciphera Pharmaceuticals are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Deciphera Pharmaceuticals stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von Deciphera Pharmaceuticals

Our stock analysis for Deciphera Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Deciphera Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.